

Muttenz, 19 June 2024

Medius secures succession and future-proof partnership with regenold

Dear valued client,

We are excited to announce a significant development in the future of Medius AG. On 11 June 2024, regenold GmbH has acquired the majority of shares in Medius AG, marking a new chapter for our company.

Founded in 1994, regenold offers a comprehensive range of regulatory services, from development to market access and life cycle management for pharmaceuticals, medical devices, cosmetics, food supplements and other products. Headquartered in Badenweiler, Germany, regenold serves an international client base in addition with subsidiaries in the UK, Switzerland and Portugal as well as its proprietary global network, regulanet. The company remains under the management of the founding Regenold family.

Dr. Urs Rickenbacher, the founder and former sole owner of Medius, sought a strategic partner for succession. He found regenold to be a perfect fit due to its similar objectives and compatible working culture. The partnership ensures the continued high quality of services and further development of Medius.

Following the acquisition, Dr. Rickenbacher will be gradually stepping down as Managing Director of Medius but will continue to support the company as an active board member. He will also continue to provide consulting services for selected topics. The new management team will include Arina Mathys, a long-standing project leader at Medius with expertise in regulatory affairs, quality management and distribution, and Dr. Manuel Vögtli, a co-shareholder, who currently heads regenold swiss AG, which will be integrated into Medius.

We at Medius are proud to join the regenold group of companies. You, as our valued client, can be assured that this change in ownership will not affect our relationship with you or the quality of our services. We will continue to operate with our existing experienced team under the existing company name in Muttenz. Additionally, regenold will complement Medius with expertise and services in clinical and pre-clinical development and the medical device sector. Notably, regenold is a leader in regulatory services for borderline products, drug-device combination products, and digital health technologies, such as DiGA apps in Germany. The proximity of Medius and regenold offices, just 40 km apart across the border in Germany, will further facilitate collaboration between our teams.

We thank you for your continued trust in Medius. Should you have any questions, please feel free to reach out to us.



Dr. Max Regenold
President of the board



Dr. Urs Rickenbacher
Member of the board